This article first appeared on GuruFocus .
Release Date: November 04, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Alembic Pharmaceuticals Ltd ( BOM:533573 ) reported a 16% year-on-year revenue growth for Q2, driven by higher volumes and new product launches.
-
The company's international business showed strong performance with a 31% growth in the rest of the world markets and a 21% growth in the US market.
-
Alembic Pharmaceuticals Ltd ( BOM:533573 ) completed the acquisition of Utility Therapeutics, marking its entry into the branded segment in the US market.
-
The company maintained a gross margin of 73% for the quarter, consistent with the previous year.
-
Alembic Pharmaceuticals Ltd ( BOM:533573 ) plans to launch 4 to 5 new products in Q3 and another 4 to 5 in Q4, indicating a strong pipeline for future growth.
Negative Points
-
The company faced continued pricing pressure in the US generics and API markets.
-
There was a significant increase in R&D expenses by 41% year-on-year, impacting profitability.
-
Net debt levels increased due to borrowing for working capital and the acquisition of Utility Therapeutics.
-
The India branded business experienced a marginal impact on growth due to GST 2.0 implementation and festive season disruptions.
-
Alembic Pharmaceuticals Ltd ( BOM:533573 ) anticipates a near-term profitability hit due to investments in the US branded segment and field force expansion.
Q & A Highlights
-
Warning! GuruFocus has detected 3 Warning Signs with BOM:533573.
-
Is BOM:533573 fairly valued? Test your thesis with our free DCF calculator.
Q: Can you explain the sharp increase in R&D expenses this quarter and where the majority of the spending went? A: The increase in R&D expenses is primarily due to investments in formulation development, particularly in injectables and complex injectors. We are also working on peptides and GLP-1s, such as semaglutide and tirzepatide, which are part of our long-term strategy. (Respondent: Executive Director)
Q: What are your plans for the branded portfolio in the US market, and what kind of investment are you planning for this category? A: We are building a field force to promote our products, starting with high-prescribing doctors in women's health. Initially, there will be a profitability hit, but we expect significant ramp-up in prescriptions over time. We are also exploring in-licensing opportunities to expand our portfolio. (Respondent: Managing Director)
Q: What has led to the strong growth in the Rest of the World (ROW) market and API, especially given the muted demand in recent quarters? A: The ROW generics market has been a strong growth area for us, with a CAGR of almost 20% over the past 7-10 years. This quarter's 30% growth is exceptional due to a low base last year. For APIs, while the market has been sluggish, we saw some development quantities that contributed to growth this quarter. (Respondent: CFO)
Q: Can you elaborate on the investments and potential losses associated with the utility therapeutics acquisition? A: The acquisition involves milestone payments totaling $12 million over time. Operational costs will primarily be for onboarding the field force. We plan to gradually ramp up the field force as we gain momentum in sales. (Respondent: Senior VP of Finance)
Q: How is the Indian business performing, particularly in segments like animal health and gynecology? A: The animal health segment continues to outperform, and gynecology is also doing well. We expect better than IPM growth as these segments continue to trend upward. (Respondent: Managing Director)
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
